市場調査レポート
商品コード
1344583

リキッドバイオプシー市場:癌別、用途別、バイオマーカー別、場所別、製品別、価格と数量の見通し - エグゼクティブ/コンサルタントガイドとカスタマイズ予測/分析付き(2023年~2027年)

Liquid Biopsy Markets By Cancer, Usage, Biomarker, Place, & Product With Price And Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027

出版日: | 発行: Howe Sound Research | ページ情報: 英文 540 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
リキッドバイオプシー市場:癌別、用途別、バイオマーカー別、場所別、製品別、価格と数量の見通し - エグゼクティブ/コンサルタントガイドとカスタマイズ予測/分析付き(2023年~2027年)
出版日: 2023年08月14日
発行: Howe Sound Research
ページ情報: 英文 540 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

体外血液検査で癌DNAを同定することで、癌診断に革命が起きています。この技術により、広範な癌スクリーニング検査の可能性が生まれました。

Illumina は現在、癌の早期発見に役立つCCGA(Circulating Cell-Free Genome Atlas)に取り組んでいます。技術の進歩は市場よりも速いです。血液サンプルから病状を決定的に特定する新技術は、高価な侵襲的外科的生検法に取って代わる態勢を整えています。市場はまだ初期段階にありますが、新たな成長段階に入ったところです。医療業界に与える影響は甚大です。

当レポートは、世界のリキッドバイオプシー市場について調査し、市場の概要とともに、癌別、用途別、バイオマーカー別、場所別、製品別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

第3章 市場概要

  • 市場参入組織
    • 学術研究機関
    • 診断試験開発者
    • 計装サプライヤー
    • 薬品・試薬メーカー
    • 病理サプライヤー
    • 独立系臨床検査室
    • 公共の国立/地域研究所
    • 病院検査室
    • 臨床検査室
    • 監査機関
    • 認証機関
  • 生検の使用
  • 生検部位
  • 今日の状況- 生検分析
  • 癌リキッドバイオプシー技術の証拠
  • 癌治療プロトコル
  • 産業構造の関与

第4章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 計測と自動化
  • 診断技術開発

第5章 最近の発展

第6章 主要参入企業のプロファイル

  • Abbott Laboratories
  • AccuraGen Inc.
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agilent/Dako
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • Applied DNA Sciences
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Burning Rock
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • CellCarta
  • CellMax Life
  • Cepheid(Danaher)
  • Circulogene
  • Cizzle Biotech
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Dxcover
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exact Sciences
  • Fluxion Biosciences
  • Freenome
  • Fyr Diagnostics
  • GeneFirst Ltd.
  • Genetron Holdings
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • Haystack Oncology
  • HeiScreen
  • Helomics
  • iCellate
  • ICON PLC
  • Illumina
  • Incell Dx
  • Inivata
  • INOVIQ
  • Integrated Diagnostics
  • Invitae Corporation
  • Janssen Diagnostics
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • Novogene Bioinformatics Technology Co., Ltd.
  • On-Chip Biotechnologies
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • PamGene
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Precision Medicine Group
  • PrecisionMed
  • Predicine
  • Promega
  • Qiagen
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Standard BioTools
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Todos Medical
  • Veracyte
  • Volition
  • Vortex Biosciences

第7章 世界のリキッドバイオプシー市場

  • 世界市場概要、国別
  • 世界市場- 概要、癌別
  • 世界市場- 概要、用途別
  • 世界市場- 概要、場所別
  • 世界市場- 概要、マーカー別
  • 世界市場- 概要、製品別

第8章 世界のリキッドバイオプシー市場- 癌別

  • 乳癌
  • 大腸癌
  • 子宮頸癌
  • 肺癌
  • 前立腺癌
  • その他

第9章 世界のリキッドバイオプシー市場- 用途別

  • スクリーニング
  • 診断
  • 治療
  • 経過観察

第10章 世界のリキッドバイオプシー市場- 場所別

  • 病院検査室
  • ラボサービス
  • 研究室外来
  • その他

第11章 世界のリキッドバイオプシー市場- マーカー別

  • 循環腫瘍細胞
  • 無細胞DNA
  • 小胞
  • その他

第12章 世界のリキッドバイオプシー市場- 製品別

  • キット
  • 装置
  • サービス

第13章 付録

図表

Table of Tables

  • Table 1: Market Players by Type
  • Table 2: Biopsy Sites
  • Table 3: LB Clinical Applications by Entity
  • Table 4: Advantages of Liquid Biopsy in Screening Market
  • Table 5: Outlook-Phases of Liquid Biopsy Adoption by Year
  • Table 6: Five Factors Driving Growth
  • Table 7: Factors Limiting Growth
  • Table 8: Key Diagnostic Laboratory Technology Trends
  • Table 9: Next Generation Sequencing Technologies - Speed and Cost
  • Table 10: Global Market by Region
  • Table 11: Global Market by Cancer
  • Table 12: Global Market by Usage
  • Table 13: Global Market by Place
  • Table 14: Global Market by Marker
  • Table 15: Global Market by Product
  • Table 16: Breast by Country
  • Table 17: Breast by Country Price
  • Table 18: Breast by Country Volume
  • Table 19: Colorectal by Country
  • Table 20: Colorectal by Country Price
  • Table 21: Colorectal by Country Volume
  • Table 22: Cervical by Country
  • Table 23: Cervical by Country Price
  • Table 24: Cervical by Country Volume
  • Table 25: Lung by Country
  • Table 26: Lung by Country Price
  • Table 27: Lung by Country Volume
  • Table 28: Prostate by Country
  • Table 29: Prostate by Country Price
  • Table 30: Prostate by Country Volume
  • Table 31: Other by Country
  • Table 32: Other by Country Price
  • Table 33: Other by Country Volume
  • Table 34: Screening by Country
  • Table 35: Diagnostic by Country
  • Table 36: Therapy by Country
  • Table 37: Monitor by Country
  • Table 38: Hospital Lab by Country
  • Table 39: Lab Service by Country
  • Table 40: Lab Outpatient by Country
  • Table 41: Other Lab by Country
  • Table 42: Circulating Tumor Cell by Country
  • Table 43: Cell Free DNA by Country
  • Table 44: Vesicle by Country
  • Table 45: Other Marker by Country
  • Table 46: Kits by Country
  • Table 47: Instruments by Country
  • Table 48: Service by Country
  • Table 49: Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Global Healthcare Spending Picture
  • Figure 2: The Global Lab Test Pie
  • Figure 3: The Road to Diagnostics
  • Figure 4: Comparison of Liquid vs Tissue Biopsy
  • Figure 5: Entities Analyzed in liquid Biopsy
  • Figure 6: Characteristics of Different Vesicle Types
  • Figure 7: The Changing Age of World Population
  • Figure 8: Health Care Consumption by Age
  • Figure 9: Cancer Incidence-Age at Diagnosis
  • Figure 10: Global Market Regional Share Chart
  • Figure 11: Global Market by Cancer-Base vs. Final
  • Figure 12: Global Market by Cancer Base Year
  • Figure 13: Global Market by Cancer End Year
  • Figure 14: Cancer Share by Year
  • Figure 15: Cancer Segments Growth
  • Figure 16: Global Market by Usage-Base vs. Final
  • Figure 17: Global Market by Usage Base Year
  • Figure 18: Global Market by Usage End Year
  • Figure 19: Usage Share by Year
  • Figure 20: Usage Segments Growth
  • Figure 21: Global Market by Place-Base vs. Final
  • Figure 22: Global Market by Place Base Year
  • Figure 23: Global Market by Place End Year
  • Figure 24: Place Share by Year
  • Figure 25: Place Segments Growth
  • Figure 26: Global Market by Marker-Base vs. Final
  • Figure 27: Global Market by Marker Base Year
  • Figure 28: Global Market by Marker End Year
  • Figure 29: Marker Share by Year
  • Figure 30: Marker Segments Growth
  • Figure 31: Global Market by Product-Base vs. Final
  • Figure 32: Global Market by Product Base Year
  • Figure 33: Global Market by Product End Year
  • Figure 34: Product Share by Year
  • Figure 35: Product Segments Growth
  • Figure 36: Breast Growth
  • Figure 37: Colorectal Diagnostics Growth
  • Figure 38: Cervical Growth
  • Figure 39: Lung Growth
  • Figure 40: Prostate Growth
  • Figure 41: Other Growth
  • Figure 42: Screening Growth
  • Figure 43: Diagnostic Growth
  • Figure 44: Therapy Growth
  • Figure 45: Monitor Growth
  • Figure 46: Hospital Lab Growth
  • Figure 47: Lab Service Growth
  • Figure 48: Lab Outpatient Growth
  • Figure 49: Other Lab Growth
  • Figure 50: Circulating Tumor Cell Growth
  • Figure 51: Cell Free DNA Growth
  • Figure 52: Vesicle Growth
  • Figure 53: Other Marker Growth
  • Figure 54: Kits Growth
  • Figure 55: Instruments Growth
  • Figure 56: Service Growth
目次

OVERVIEW:

The Screening, Diagnostic, Therapy Selection, Minimal Residual Disease and Screening Market Potential are all explored in this report. We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread cancer screening tests.

Illumina is now working on the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved into a new growth phase. The impact on the health care industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Liquid Biopsy Market-Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing, Sales, and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What is Liquid Biopsy?
  • 2.2. The Sequencing Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Instrumentation Supplier
    • 3.1.4. Chemical/Reagent Supplier
    • 3.1.5. Pathology Supplier
    • 3.1.6. Independent Clinical Laboratory
    • 3.1.7. Public National/regional Laboratory
    • 3.1.8. Hospital Laboratory
    • 3.1.9. Physicians Office Lab (POLS)
    • 3.1.10. Audit Body
    • 3.1.11. Certification Body
  • 3.2. Using Biopsies
    • 3.2.1. Cancer
    • 3.2.2. Precancerous conditions
    • 3.2.3. Inflammatory conditions
  • 3.3. Biopsy Sites
  • 3.4. The Situation Today - Biopsy Analysis
  • 3.5. Evidence of Cancer-Liquid Biopsy Technology
    • 3.5.1. The Big Picture on Liquid Biopsy Technology
    • 3.5.2. The Role of CTCs
    • 3.5.3. Application of CTCs
    • 3.5.4. CellSearch Detection- Ultimate Sensitivity
    • 3.5.5. Epic Sciences Detection- Imaging Takes the Lead
    • 3.5.6. Maintrac Detection - The Microscope
    • 3.5.7. Other Methods
    • 3.5.8. ctDNA Role
    • 3.5.9. ctDNA Applications
    • 3.5.10. Exosomes and Micro Vesicles - New Kid on the Block
    • 3.5.11. The Multiple Play
  • 3.6. Cancer Treatment Protocol Under Siege
    • 3.6.1. Issues to Liquid Biopsy Adoption - Double Diagnostics
    • 3.6.2. The Cancer Screening Market Opportunity
      • 3.6.2.1. GRAIL - What Is It?
    • 3.6.3. Cancer Management vs. Diagnosis
      • 3.6.3.1. The Role of Risk Assessment
      • 3.6.3.2. Managing Therapy
      • 3.6.3.3. Monitoring Disease - What Is It?
    • 3.6.4. Phases of Adoption - Looking into The Future
    • 3.6.5. The Promise of Liquid Biopsy
  • 3.7. Structure of Industry Plays a Part
    • 3.7.1. Hospital Testing Share
    • 3.7.2. Economies of Scale
      • 3.7.2.1. Hospital vs. Central Lab
    • 3.7.3. Physician Office Lab's
    • 3.7.4. Physician's and POCT

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Non-Invasive Game Changer
    • 4.1.2. Lower Cost
    • 4.1.3. Greater Accuracy
    • 4.1.4. Wide Range of Potential Uses
    • 4.1.5. Aging Population
  • 4.2. Factors Limiting Growth
    • 4.2.1. Lower prices
    • 4.2.2. Lack of Standards
    • 4.2.3. Protocol Resistance
    • 4.2.4. Initial Adoption Cost
    • 4.2.5. Conclusion
  • 4.3. Instrumentation and Automation
    • 4.3.1. Instruments Key to Market Share
    • 4.3.2. Bioinformatics Plays a Role
  • 4.4. Diagnostic Technology Development
    • 4.4.1. Next Generation Sequencing Fuels a Revolution
    • 4.4.2. Impact of NGS on pricing
    • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4. CGES Testing, A Brave New World
    • 4.4.5. Biochips/Giant magneto resistance based assay

5. Liquid Biopsy Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. Liquid Biopsy Shortens Time to Treatment
  • 5.3. Guardant Health MRD Test Garners Coverage
  • 5.4. IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership
  • 5.5. FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic
  • 5.6. Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test
  • 5.7. GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test
  • 5.8. Sophia Genetics to Commercialize Liquid Biopsy Test
  • 5.9. Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx
  • 5.10. Liquid Biopsy Startup Haystack Oncology Raises $56M
  • 5.11. Hedera Dx to Launch Liquid Biopsy Streamlined Platform
  • 5.12. PamGene Expanding Liquid Biopsy Assays
  • 5.13. Liquid Biopsy Firm Hedera Dx Raises €14M
  • 5.14. MDxHealth Plans One-Stop Shop for Prostate Cancer Dx
  • 5.15. Precision Oncology Dx Access Varies Widely in Europe
  • 5.16. Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic
  • 5.17. Predicine Receives CE Mark for Blood and Urine Liquid Biopsy
  • 5.18. BillionToOne Launches First Liquid Biopsy Products
  • 5.19. Dxcover Advances Multicancer Detection Platform
  • 5.20. CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test
  • 5.21. Illumina Sues Guardant Health Over Patents
  • 5.22. Invitae to Expand Cancer Testing Portfolio
  • 5.23. Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
  • 5.24. IVBH Bio Takes Aim at With Liquid Biopsy Incubator
  • 5.25. Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
  • 5.26. Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
  • 5.27. BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
  • 5.28. EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
  • 5.29. Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding
  • 5.30. Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
  • 5.31. Bio-Techne to Acquire Asuragen for up to $320M
  • 5.32. Personalis Broadens Liquid Biopsy Offering
  • 5.33. Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
  • 5.34. Delfi Diagnostics Plans Multi-Cancer Screening Test
  • 5.35. Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
  • 5.36. Liquid Biopsy NGS Panels-Diverse Test Claims
  • 5.37. CMS Colon Cancer Screening Memo Bodes Well for Assays
  • 5.38. Natera Liquid Biopsy Test Coverage to Expand
  • 5.39. Freenome Closes Financing to Support Early Cancer Detection Trial
  • 5.40. C$2.6M Liquid Biopsy Initiative
  • 5.41. NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
  • 5.42. Liquid Biopsy Shows Promise as Screen for Cancers
  • 5.43. Inivata launches RaDaR™ for the detection of residual disease and recurrence
  • 5.44. Liquid Biopsy Assay Detects 50+ Types of Cancer
  • 5.45. Liquid Biopsy Study Confirms Concordance with Tissue Biopsy

6. Profiles of Key Players

  • 6.1. Abbott Laboratories
  • 6.2. AccuraGen Inc.
  • 6.3. Acuamark Diagnostics
  • 6.4. Admera Health, LLC
  • 6.5. Agilent/Dako
  • 6.6. Amoy Diagnostics Co., Ltd.
  • 6.7. Anchor Dx
  • 6.8. ANGLE plc
  • 6.9. Applied DNA Sciences
  • 6.10. ARUP Laboratories
  • 6.11. AVIVA Systems Biology
  • 6.12. Baylor Miraca Genetics Laboratories
  • 6.13. Beckman Coulter Diagnostics
  • 6.14. Becton, Dickinson and Company
  • 6.15. BGI Genomics Co. Ltd
  • 6.16. Bioarray Genetics
  • 6.17. Biocartis
  • 6.18. Biocept, Inc.
  • 6.19. Biodesix Inc.
  • 6.20. BioFluidica
  • 6.21. bioMérieux Diagnostics
  • 6.22. Bioneer Corporation
  • 6.23. Bio-Rad Laboratories, Inc
  • 6.24. Bio-Techne
  • 6.25. Bioview
  • 6.26. Bolidics
  • 6.27. Boreal Genomics
  • 6.28. Burning Rock
  • 6.29. Cardiff Oncology
  • 6.30. Caris Molecular Diagnostics
  • 6.31. CellCarta
  • 6.32. CellMax Life
  • 6.33. Cepheid (Danaher)
  • 6.34. Circulogene
  • 6.35. Cizzle Biotech
  • 6.36. Clinical Genomics
  • 6.37. Cytolumina Technologies Corp.
  • 6.38. Datar Cancer Genetics Limited
  • 6.39. Diagnologix LLC
  • 6.40. Dxcover
  • 6.41. Enzo Biochem
  • 6.42. Epic Sciences
  • 6.43. Epigenomics AG
  • 6.44. Eurofins Scientific
  • 6.45. Exact Sciences
  • 6.46. Fluxion Biosciences
  • 6.47. Freenome
  • 6.48. Fyr Diagnostics
  • 6.49. GeneFirst Ltd.
  • 6.50. Genetron Holdings
  • 6.51. GILUPI Nanomedizin
  • 6.52. Guardant Health
  • 6.53. HansaBiomed
  • 6.54. Haystack Oncology
  • 6.55. HeiScreen
  • 6.56. Helomics
  • 6.57. iCellate
  • 6.58. ICON PLC
  • 6.59. Illumina
  • 6.60. Incell Dx
  • 6.61. Inivata
  • 6.62. INOVIQ
  • 6.63. Integrated Diagnostics
  • 6.64. Invitae Corporation
  • 6.65. Janssen Diagnostics
  • 6.66. Lunglife AI Inc
  • 6.67. MDNA Life SCIENCES, Inc.
  • 6.68. MDx Health
  • 6.69. Menarini Silicon Biosystems
  • 6.70. Mesa Laboratories, Inc.
  • 6.71. Millipore Sigma
  • 6.72. Miltenyi Biotec
  • 6.73. miR Scientific
  • 6.74. Myriad Genetics/Myriad RBM
  • 6.75. NantHealth, Inc.
  • 6.76. Natera
  • 6.77. NeoGenomics
  • 6.78. Novogene Bioinformatics Technology Co., Ltd.
  • 6.79. On-Chip Biotechnologies
  • 6.80. Oncocyte
  • 6.81. OncoDNA
  • 6.82. Oxford Nanopore Technologies
  • 6.83. PamGene
  • 6.84. Panagene
  • 6.85. Perkin Elmer
  • 6.86. Personal Genome Diagnostics
  • 6.87. Precision Medicine Group
  • 6.88. PrecisionMed
  • 6.89. Predicine
  • 6.90. Promega
  • 6.91. Qiagen
  • 6.92. Rarecells SAS
  • 6.93. RareCyte
  • 6.94. Roche Molecular Diagnostics
  • 6.95. Screencell
  • 6.96. Siemens Healthineers
  • 6.97. simfo GmbH
  • 6.98. Singlera Genomics Inc.
  • 6.99. Standard BioTools
  • 6.100. Sysmex Inostics
  • 6.101. Tempus Labs, Inc.
  • 6.102. Thermo Fisher Scientific Inc.
  • 6.103. Todos Medical
  • 6.104. Veracyte
  • 6.105. Volition
  • 6.106. Vortex Biosciences

7. The Global Market for Liquid Biopsy Diagnostics

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart-Global Market by Country
  • 7.2. Global Market by Cancer-Overview
    • 7.2.1. Table - Global Market by Cancer
    • 7.2.2. Chart - Global Market by Cancer - Base/Final Year Comparison
    • 7.2.3. Chart - Global Market by Cancer - Base Year
    • 7.2.4. Chart - Global Market by Cancer - End Year
    • 7.2.5. Chart - Global Market by Cancer - Share by Year
    • 7.2.6. Chart - Global Market by Cancer - Segments Growth
  • 7.3. Global Market by Usage-Overview
    • 7.3.1. Table - Global Market by Usage
    • 7.3.2. Chart - Global Market by Usage - Base/Final Year Comparison
    • 7.3.3. Chart - Global Market by Usage - Base Year
    • 7.3.4. Chart - Global Market by Usage - End Year
    • 7.3.5. Chart - Global Market by Usage - Share by Year
    • 7.3.6. Chart - Global Market by Usage - Segments Growth
  • 7.4. Global Market by Place-Overview
    • 7.4.1. Table - Global Market by Place
    • 7.4.2. Chart - Global Market by Place - Base/Final Year Comparison
    • 7.4.3. Chart - Global Market by Place - Base Year
    • 7.4.4. Chart - Global Market by Place - End Year
    • 7.4.5. Chart - Global Market by Place - Share by Year
    • 7.4.6. Chart - Global Market by Place - Segments Growth
  • 7.5. Global Market by Marker-Overview
    • 7.5.1. Table - Global Market by Marker
    • 7.5.2. Chart - Global Market by Marker - Base/Final Year Comparison
    • 7.5.3. Chart - Global Market by Marker - Base Year
    • 7.5.4. Chart - Global Market by Marker - End Year
    • 7.5.5. Chart - Global Market by Marker - Share by Year
    • 7.5.6. Chart - Global Market by Marker - Segments Growth
  • 7.6. Global Market by Product-Overview
    • 7.6.1. Table - Global Market by Product
    • 7.6.2. Chart - Global Market by Product - Base/Final Year Comparison
    • 7.6.3. Chart - Global Market by Product - Base Year
    • 7.6.4. Chart - Global Market by Product - End Year
    • 7.6.5. Chart - Global Market by Product - Share by Year
    • 7.6.6. Chart - Global Market by Product - Segments Growth

8. Global Liquid Biopsy Diagnostic Markets - By Cancer

  • 8.1. Breast
    • 8.1.1. Table Breast - by Country
    • 8.1.2. Table Breast - by Country, Price
    • 8.1.3. Table Breast - by Country Volume
    • 8.1.4. Chart-Breast Growth
  • 8.2. Colorectal
    • 8.2.1. Table Colorectal - by Country
    • 8.2.2. Table Colorectal - by Country, Price
    • 8.2.3. Table Colorectal - by Country, Volume
    • 8.2.4. Chart-Colorectal Growth
  • 8.3. Cervical
    • 8.3.1. Table Cervical - by Country
    • 8.3.2. Table Cervical - by Country, Price
    • 8.3.3. Table Cervical - by Country, Volume
    • 8.3.4. Chart-Cervical Growth
  • 8.4. Lung
    • 8.4.1. Table Lung - by Country
    • 8.4.2. Table Lung - by Country, Price
    • 8.4.3. Table Lung - by Country, Volume
    • 8.4.4. Chart-Lung Growth
  • 8.5. Prostate
    • 8.5.1. Table Prostate - by Country
    • 8.5.2. Table Prostate - by Country, Price
    • 8.5.3. Table Prostate - by Country, Volume
    • 8.5.4. Chart - Prostate Growth
  • 8.6. Other
    • 8.6.1. Table Other - by Country
    • 8.6.2. Table Other - by Country, Price
    • 8.6.3. Table Other - by Country, Volume
    • 8.6.4. Chart-Other Growth

9. Global Liquid Biopsy Diagnostic Markets - by Usage

  • 9.1. Screening
    • 9.1.1. Table Screening - by Country
  • 9.2. Chart-Screening Growth
  • 9.3. Diagnostic
    • 9.3.1. Table Diagnostic - by Country
    • 9.3.2. Chart-Diagnostic Growth
  • 9.4. Therapy
    • 9.4.1. Table Therapy - by Country
    • 9.4.2. Chart-Therapy Growth
  • 9.5. Monitor
    • 9.5.1. Table Monitor - by Country
    • 9.5.2. Chart-Monitor Growth

10. Global Liquid Biopsy Diagnostic Markets - by Place

  • 10.1. Hospital Lab
    • 10.1.1. Table Hospital Lab - by Country
    • 10.1.2. Chart-Hospital Lab Growth
  • 10.2. Lab Service
    • 10.2.1. Table Lab Service - by Country
    • 10.2.2. Chart-Lab Service Growth
  • 10.3. Lab Outpatient
    • 10.3.1. Table Lab Outpatient - by Country
    • 10.3.2. Chart-Lab Outpatient Growth
  • 10.4. Other Lab
    • 10.4.1. Table Other Lab - by Country
    • 10.4.2. Chart-Other Lab Growth

11. Global Liquid Biopsy Diagnostic Markets - by Marker

  • 11.1. Circulating Tumor Cell
    • 11.1.1. Table Circulating Tumor Cell - by Country
    • 11.1.2. Chart-Circulating Tumor Cell Growth
  • 11.2. Cell Free DNA
    • 11.2.1. Table Cell Free DNA - by Country
    • 11.2.2. Chart-Cell Free DNA Growth
  • 11.3. Vesicle
    • 11.3.1. Table Vesicle - by Country
    • 11.3.2. Chart-Vesicle Growth
  • 11.4. Other Marker
    • 11.4.1. Table Other Marker - by Country
    • 11.4.2. Chart-Other Marker Growth

12. Global Liquid Biopsy Diagnostic Markets - by Product

  • 12.1. Kits
    • 12.1.1. Table Kits - by Country
    • 12.1.2. Chart-Kits Growth
  • 12.2. Instruments
    • 12.2.1. Table Instruments - by Country
    • 12.2.2. Chart-Instruments Growth
  • 12.3. Service
    • 12.3.1. Table Service - by Country
    • 12.3.2. Chart-Service Growth

13. Appendices

  • 13.1. United States Medicare System: Clinical Laboratory Fees Schedule